MURANO To Drive AbbVie/Roche's Venetoclax In CLL

 
• By Alex Shimmings
  
Generate a summary of this article
Listen to this article
Beta

Top-line MURANO data support Venclexta's current conditional approvals and expand its use into a broader population that should radically boost sales.

Roots
MURANO Data Buttressing Future Growth • Source: Shutterstock

AbbVie Inc. and Roche are in line for a sales boost for their BCL-2 inhibitor, Venclexta/Venclyxto (venetoclax), after top-line data show success for the Phase III MURANO study of the small-molecule drug in combination with the anti-CD20 product rituximab (Roche's MabThera/Rituxan) in relapsed or refractory chronic lymphocytic leukaemia (CLL), a far larger population than its current label covers.

The 389-patient trial has met its primary endpoint, giving a significant improvement in progression-free survival when used in combination with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D